Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 · New England Journal of Medicine · 1,135 citations
https://doi.org/10.1056/nejmoa1413687
A
Adaani Frost
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
233
Papers
28.2K
Citations
62
h-index
116
i10-index
Adaani Frost is an academic researcher from Houston Methodist. The author has contributed to research in topics: Pulmonary Hypertension Research and Treatments & Transplantation: Methods and Outcomes & Cardiovascular Issues in Pregnancy. The author has an h-index of 62, co-authored 199 publications.
ORCID: 0000-0002-5566-2103Papers by this author
worksGenetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
2018 · The Lancet Respiratory Medicine · 203 citations
https://doi.org/10.1016/s2213-2600(18)30409-0
Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
2014 · CHEST Journal · 46 citations
https://doi.org/10.1378/chest.14-1004
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
2018 · The Journal of Heart and Lung Transplantation · 28 citations
https://doi.org/10.1016/j.healun.2018.11.006
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
2019 · Respiratory Research · 17 citations
https://doi.org/10.1186/s12931-019-1180-1
An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
2022 · Scientific Reports · 11 citations
https://doi.org/10.1038/s41598-022-22434-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat